Study on Using Fedratinib to Prevent Cancer Relapse After Transplant in Patients with Myeloproliferative Neoplasms

Inclusion Criteria

• Be at least 18 years old.
• Have a performance status score of 0, 1, or 2, indicating good overall health.
• Understand and agree to sign a consent form before any study procedures.
• Be willing to follow the study schedule and requirements.
• Have a specific type of blood cancer (Philadelphia chromosome negative myeloproliferative disease) and have undergone a first stem cell transplant.
• Have successful engraftment, meaning the donor cells have taken hold, with specific blood cell counts.
• No signs of cancer progression based on specific criteria.
• If you have skin-related graft-versus-host disease (GVHD), it must be controlled with low-dose prednisone.
• Women who can become pregnant must have a negative pregnancy test and agree to use effective birth control during the study and for 30 days after.
• Men must agree to use a condom during sexual contact with women who can become pregnant and for 30 days after stopping the study drug.

Exclusion Criteria

• Have active gut or liver GVHD requiring treatment.
• Have used a JAK2 inhibitor within 14 days before joining the study.
• Have certain abnormal lab results.
• Be pregnant or breastfeeding.
• Have a history of Wernicke's encephalopathy or symptoms of it.
• Be taking medications that strongly affect the liver enzyme CYP3A4.
• Have low thiamine levels that are not corrected before starting the study drug.
• Be on certain cancer treatments or medications like aspirin over 150 mg daily.
• Have had major surgery within 28 days before starting the study drug.
• Have chronic liver disease or uncontrolled heart failure.
• Have active HIV, Hepatitis B, or Hepatitis C infections.
• Have a serious active infection.
• Have a condition that affects the absorption of oral medication.
• Have another active cancer requiring treatment, except for certain skin cancers.
• Have more than 10% bone marrow blasts.
• Be unable to swallow capsules.